Advancing the delivery of glucagon

Gvoke is the first autoinjector for severe hypoglycemia1


Gvoke HypoPen™3
Gvoke HypoPen™ (glucagon injection)
  • Premixed and ready-to-go, so it is easy-to-use2,4
  • Anyone can use in 2 simple steps2,3
  • No visible needle
  • No refrigeration required1,5
  • Available in 2 premeasured doses (0.5 mg for children and 1.0 mg for adults)
References: 1. Gvoke [prescribing information]. Chicago, IL: Xeris Pharmaceuticals, Inc. 2. U.S. Food and Drug Administration. Search results for "glucagon." Drugs@FDA: FDA approved drug products. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process. Accessed September 13, 2019. 3. Gvoke HypoPen [instructions for use]. Chicago, IL: Xeris Pharmaceuticals, Inc; 2020. 4. Valentine V, Newswanger B, Prestrelski S, Andre AD, Garibaldi M. Human factors usability and validation studies of a glucagon autoinjector in a simulated severe hypoglycemia rescue situation. Diabetes Technol Ther. 2019;21(9):522-530. 5. Data on file. [CSR, p. 76] [Adult Study (301 and 303)] [Ped. Study (302)] [Safety DOF for Xeris Launch Summary] pStability, p.31]